
KalVista Pharma (KALV) Stock Forecast & Price Target
KalVista Pharma (KALV) Analyst Ratings
Bulls say
KalVista Pharmaceuticals Inc. is well-positioned for a successful launch of sebetralstat, an oral therapy that offers a convenient and effective alternative to existing on-demand treatments for hereditary angioedema (HAE), as evidenced by physician sentiment regarding increased patient adherence to oral medications. The company's conservative projections estimate approximately $400 million in worldwide sales at peak, underpinned by encouraging data presentation at recent industry conferences that demonstrated sebetralstat's efficacy, particularly among adolescents. Additionally, the favorable landscape of the stabilized HAE market, combined with the anticipated June 17 PDUFA date and a high likelihood of approval, suggests potential for premium pricing and rapid product adoption that could surpass initial expectations.
Bears say
KalVista Pharmaceuticals Inc. reported a significant net loss of $44.3 million, or $0.92 per share, for the third quarter of fiscal year 2025, indicating ongoing financial struggles as the company likely incurs further losses through the early stages of sebetralstat's launch. Additionally, the company's prospects for future growth appear limited due to its reliance on sebetralstat; failure or underperformance of this product, paired with a lack of alternative developmental candidates, raises concerns about its ability to secure necessary funding and achieve projected revenue. Furthermore, regulatory risks surrounding the approval and commercialization of sebetralstat, alongside potential skepticism from patients and physicians regarding its efficacy for certain types of hereditary angioedema attacks, contribute to an overall negative outlook on the company’s financial health.
This aggregate rating is based on analysts' research of KalVista Pharma and is not a guaranteed prediction by Public.com or investment advice.
KalVista Pharma (KALV) Analyst Forecast & Price Prediction
Start investing in KalVista Pharma (KALV)
Order type
Buy in
Order amount
Est. shares
0 shares